Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

JP Morgan hikes targets for defence stocks on European spending hopes

(Sharecast News) - JPMorgan has hiked target prices across the listed European defence sector by an average 25% on the back of an anticipated "rearmament cycle" across the continent. JPMorgan raised target prices for the following UK stocks: Babcock (from 760p to 900p), BAE Systems (from 1,630p to 1,725p), IMI (from 2,275p to 2,290p), Qinetiq (from 535p to 570p) and Rolls-Royce (655p to 900p). All five stocks are rated 'overweight' by the bank.

In March of last year, JPMorgan predicted that a rearmament cycle in Europe would last for at least a decade due to a new political consensus that the continent would need to address "30 years of underinvestment in defence".

The prediction was also based on the scenario that the US would be less willing to subsidise Europe's defence, and that Europe would eventually produce more of its own military equipment to reduce its reliance on America.

"In our view, the events of the last two weeks have turbo-charged this thesis," said analyst David Perry.

"In the last two weeks Denmark and the UK have announced significant increases in their defence budgets and Germany's new Chancellor has proposed a new €200bn Special Defence Fund for Germany alone. There are 30 European countries in NATO and we expect many of them will soon commit to much higher defence spending, Perry said.

The analyst told investor to expect "significant increases" in consensus estimates and company guidance in the coming months and years.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.